| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2). Ibuprofen Impurity K is a COX-1 and COX-2 inhibitor with reported IC50 values of 13 uM for COX-1 and 370 uM for COX-2, similar to its parent compound ibuprofen, contributing to its anti-inflammatory effects.
|
|---|---|
| ln Vitro |
In vitro, Ibuprofen Impurity K acts as a COX-1 and COX-2 inhibitor, with IC50 values of 13 uM and 370 uM, respectively. It is an impurity standard used primarily to quantify ibuprofen-related substances in pharmaceutical formulations. Its biological activity is assumed to be similar to that of ibuprofen, but it is not intended for therapeutic use.
|
| ln Vivo |
No detailed in vivo studies are reported for Ibuprofen Impurity K. As an impurity of ibuprofen, if present in drug products, it may contribute negligibly to the overall in vivo pharmacological effects. It is not administered alone in animal models and is primarily used for analytical rather than in vivo research applications.
|
| Enzyme Assay |
A COX inhibition assay is performed using purified ovine or human COX-1 and COX-2 enzymes. The enzymes are incubated with arachidonic acid (substrate) in the presence of serially diluted Ibuprofen Impurity K (0.1-1000 uM). The reaction is stopped, and prostaglandin (PGE2) production is measured by ELISA. The IC50 is calculated from the dose-response curve.
|
| Cell Assay |
For in vitro cellular assays, murine macrophages (RAW 264.7) are stimulated with lipopolysaccharide (LPS, 1 ug/mL) to induce COX-2 expression. Cells are treated with serially diluted Ibuprofen Impurity K (0.1-1000 uM) for 24 hours. Supernatant prostaglandin E2 (PGE2) levels are measured by ELISA. Cell viability is assessed using an MTT or CellTiter-Glo assay to confirm that observed effects are not due to cytotoxicity.
|
| Animal Protocol |
No in vivo animal studies are performed for Ibuprofen Impurity K as a standalone compound. It is a reference impurity used in the quality control of ibuprofen drug products. For impurity profiling, the compound is spiked into ibuprofen samples and analyzed by HPLC or LC-MS/MS according to pharmacopeial methods to separate and quantify known and unknown impurities.
|
| ADME/Pharmacokinetics |
Ibuprofen Impurity K has a molecular weight suitable for HPLC and LC-MS/MS analysis. Detailed pharmacokinetic parameters are not available. It is a non-therapeutic impurity standard that is not intended for in vivo administration. Its physicochemical properties are expected to be similar to ibuprofen (logP ~3.5), but it is used only for analytical purposes.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data specific to Ibuprofen Impurity K are not publicly available. As an ibuprofen-related substance, it is considered a low-level impurity and is not expected to contribute significantly to the toxicity profile of ibuprofen drug products when present within regulatory limits. Pharmacopoeias specify acceptable limits for impurities in pharmaceuticals.
|
| References | |
| Additional Infomation |
Ibuprofen Impurity K is a research-grade reference standard, not approved for clinical use. It is used in pharmaceutical quality control to meet regulatory requirements for impurity profiling of ibuprofen drug substances and drug products. It is also used in forced degradation studies and stability-indicating HPLC method development.
|
| Molecular Formula |
C10H10O3
|
|---|---|
| Molecular Weight |
178.18
|
| Exact Mass |
178.063
|
| CAS # |
43153-07-7
|
| PubChem CID |
10219663
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.687
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
192
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=CC1C=CC(C(C(=O)O)C)=CC=1
|
| InChi Key |
IAXYHYOWEQQFMC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H10O3/c1-7(10(12)13)9-4-2-8(6-11)3-5-9/h2-7H,1H3,(H,12,13)
|
| Chemical Name |
2-(4-formylphenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6123 mL | 28.0615 mL | 56.1230 mL | |
| 5 mM | 1.1225 mL | 5.6123 mL | 11.2246 mL | |
| 10 mM | 0.5612 mL | 2.8062 mL | 5.6123 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
